Preclinical obesity drug candidate shows comparable effects in mice

Artelo Biosciences' cannabinoid-based obesity treatment candidate demonstrates potential in early animal testing but remains untested in humans.

Artelo Biosciences' ex-AstraZeneca cannabinoid agonist candidate shows comparable effects to semaglutide in obese mouse models. This preclinical finding suggests possible utility for obesity treatment, though the research remains in early development. The candidate has not yet entered human clinical trials, meaning it does not currently address obesity needs for people. For the health sector, this represents a potential future pathway to more accessible weight management options—but only after rigorous human testing. The source provides no further detail about the study's scope or next steps. The source is brief and the detail sits with them.

Source: Fierce Biotech